Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Stock Information for Theratechnologies Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Theratechnologies Inc.

Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology(TM) Oncology Platform
Theratechnologies Appoints Elina Tea to its Board of Directors
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology(TM) Platform
Theratechnologies Announces Update on its Preclinical Oncology Research Program

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.